Menu
Back to Archived Journals » Gastrointestinal Cancer: Targets and Therapy » Volume 2
Critical appraisal of the role of everolimus in advanced neuroendocrine tumors of pancreatic origin
Authors Mulet-Margalef, Capdevila J
Received 20 June 2012
Accepted for publication 25 July 2012
Published 27 September 2012 Volume 2012:2 Pages 29—37
DOI https://doi.org/10.2147/GICTT.S24826
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 4
Núria Mulet-Margalef, Jaume Capdevila
Medical Oncology Department, Vall d'Hebron University Hospital, Barcelona, Spain
Abstract: For many years, the treatment of advanced pancreatic neuroendocrine tumors (pNETs) has been limited almost entirely to somatostatin analogs and streptozocin-based chemotherapy, with modest benefit. Increasing knowledge of the biologic features of pNETs has allowed the design of molecular-based clinical trials, which have taken a step forward in the management of these tumors. In this review, we discuss the molecular rationale for the development of everolimus for patients with advanced pNETs, critically review the clinical data obtained by the main studies in this setting, and discuss essential considerations based on recent findings in pNET biology for future drug development involving the phosphatidylinositol 3' kinase-AKT-mTOR pathway.
Keywords: pancreatic neuroendocrine tumors, everolimus, targeted therapies
© 2012 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.